Investors

Press Releases

Press Releases

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will be
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company
- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of
Over 30 years of experience in advancing therapeutics to commercial launch and driving companies to successful operations and strategic transactions CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the
CAMBRIDGE, Mass. , May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics , Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced
Veteran life sciences financial executive brings over 25 years finance and capital markets expertise CAMBRIDGE, Mass., Feb. 8, 2021 /PRNewswire/ -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to
Financing accelerates Werewolf's pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team CAMBRIDGE, Mass., Jan.
Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for clinical development of lead programs CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation,
CAMBRIDGE, Mass., Aug. 10, 2020 /PRNewswire/ -- Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Ellen Lubman to the company's newly created position of Chief Business Officer.
Displaying 1 - 10 of 11

Investor Contact

Alan Lada
Solebury Trout
617.221.8006
Sign up for email alerts